11 research outputs found
Heteronuclear Gd-<sup>99m</sup>Tc Complex of DTPA-Bis(histidylamide) Conjugate as a Bimodal MR/SPECT Imaging Probe
The work describes the synthesis and in vivo application
of heterotrimetallic
complexes of the type {GdÂ(H<sub>2</sub>O)Â[(MÂ(H<sub>2</sub>O)Â(CO)<sub>3</sub>)<sub>2</sub>(<b>1</b>)]} {<b>1</b> = DTPA-bisÂ(histidyl-amide); <i>M</i> = Re (<b>3a</b>); <sup>99m</sup>Tc (<b>3b</b>)} for dual modality MR/SPECT imaging. Here, the DTPA-bisÂ(histidylamide)
conjugate functions as a trinucleating chelate incorporating Gd in
the DTPA core with Re or <sup>99m</sup>Tc in the pair of histidylamide
side arms. The two complexes are chemically equivalent as revealed
by HPLC, and their “cocktail mixture” (<b>3a</b> + <b>3b</b>) has demonstrated itself to be essentially a single
bimodal imaging probe. The present system has thus overcome the sensitivity
difference problem between MRI and SPECT and paved the way for practical
applications
<sup>18</sup>F-Mefway PET Imaging of Serotonin 1A Receptors in Humans: A Comparison with <sup>18</sup>F-FCWAY
<div><p>Introduction</p><p>The purpose of this research is to evaluate the prospects for the use of 4-(<i>trans</i>-<sup>18</sup>F-fluoranylmethyl)-<i>N</i>-[2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-<i>N</i>-pyridin-2-ylcyclohexane-1-carboxamide (<sup>18</sup>F-Mefway) in comparison to <sup>18</sup>F-<i>trans</i>-4-fluoro-<i>N</i>-2-[4-(2-methoxyphenyl)piperazin-1-yl]ethyl]-<i>N</i>-(2-pyridyl)cyclohexanecarboxamide (<sup>18</sup>F-FCWAY) for the quantification of 5-HT<sub>1A</sub> receptors in human subjects.</p><p>Method</p><p>Five healthy male controls were included for two positron emission tomography (PET) studies: <sup>18</sup>F-FCWAY PET after the pretreatment with 500 mg of disulfiram and two months later, <sup>18</sup>F-Mefway PET without disulfiram. Regional time-activity curves (TACs) were extracted from nine cortical and subcortical regions in dynamic PET images. Using cerebellar cortex without vermis as reference tissue, in vivo kinetics for both radioligands were compared based on the distribution volume ratio (DVR) calculated by non-invasive Logan graphical analysis and area under the curve ratio of the TACs (AUC ratio).</p><p>Result</p><p>Although the pattern of regional uptakes in the <sup>18</sup>F-Mefway PET was similar to that of the <sup>18</sup>F-FCWAY PET (highest in the hippocampus and lowest in the cerebellar cortex), the amount of regional uptake in <sup>18</sup>F-Mefway PET was almost half of that in <sup>18</sup>F-FCWAY PET. The skull uptake in <sup>18</sup>F-Mefway PET was only 25% of that in <sup>18</sup>F-FCWAY PET with disulfiram pretreatment. The regional DVR values and AUC ratio values for <sup>18</sup>F-Mefway were 17—40% lower than those of <sup>18</sup>F-FCWAY. In contrast to a small overestimation of DVR values by AUC ratio values (< 10%) in <sup>18</sup>F-FCWAY PET, the overestimation bias of AUC ratio values was much higher (up to 21%) in <sup>18</sup>F-Mefway PET.</p><p>Conclusion</p><p>As <sup>18</sup>F-Mefway showed lower DVR values and greater overestimation bias of AUC ratio values, <sup>18</sup>F-Mefway may appear less favorable than <sup>18</sup>F-FCWAY. However, in contrast to <sup>18</sup>F-FCWAY, the resistance to <i>in vivo</i> defluorination of <sup>18</sup>F-Mefway obviates the need for the use of a defluorination inhibitor. Thus, <sup>18</sup>F-Mefway may be a good candidate PET radioligand for 5-HT<sub>1A</sub> receptor imaging in human.</p></div
Chemical structures of <sup>18</sup>F-FCWAY and <sup>18</sup>F-Mefway.
<p>Chemical structures of <sup>18</sup>F-FCWAY and <sup>18</sup>F-Mefway.</p
Axial PET images of <sup>18</sup>F-FCWAY (upper) and <sup>18</sup>F-Mefway (lower).
<p>Time-averaged images using dynamic PET images of 20–40, 60–80, and 80–100 minute, respectively.</p
Relationship between the DVR and AUC ratio values for <sup>18</sup>F-FCWAY (A) and <sup>18</sup>F-Mefway (B). Dashed lines represent identity lines.
<p>Relationship between the DVR and AUC ratio values for <sup>18</sup>F-FCWAY (A) and <sup>18</sup>F-Mefway (B). Dashed lines represent identity lines.</p
Gadolinium Complex of <sup>125</sup>I/<sup>127</sup>I‑RGD-DOTA Conjugate as a Tumor-Targeting SPECT/MR Bimodal Imaging Probe
The work describes the synthesis and in vivo application
of [GdÂ(L)Â(H<sub>2</sub>O)]·<i>x</i>H<sub>2</sub>O,
where L is a (<sup>125</sup>I/<sup>127</sup>I-RGD)- DOTA conjugate,
as a tumor-targeting SPECT/MR bimodal imaging probe. Here, (<sup>125</sup>I/<sup>127</sup>I-RGD)-DOTA signifies a “cocktail mixture”
of radioisotopic (<b>1a</b>, L = <sup>125</sup>I-RGD-DOTA) and
natural (<b>1b</b>, L = <sup>127</sup>I-RGD-DOTA) Gd complexes.
The two complexes are chemically equivalent as revealed by HPLC, and
their cocktail mixture exhibits the integrin-specific tumor enhancement,
demonstrating that they constitute essentially a single bimodal imaging
probe. Employment of a cocktail mixture thus proves to be a sole and
practical approach to overcome the sensitivity difference problem
between MRI and SPECT
Comparison of skull uptake in <sup>18</sup>F-FCWAY and <sup>18</sup>F-Mefway PET.
<p>Here, <sup>18</sup>F-FCWAY PET data were acquired with disulfiram pretreatment. Circles and error bars represent mean ± standard error of the mean (SEM) in five healthy controls (closed circle = <sup>18</sup>F-FCWAY, open circle = <sup>18</sup>F-Mefway).</p
Regional time-activity curves of <sup>18</sup>F-FCWAY (A) and <sup>18</sup>F-Mefway (B) PET.
<p>Data represent mean values for five healthy controls.</p
Voxel-wise parametric mapping for <sup>18</sup>F-FCWAY (A) and <sup>18</sup>F-Mefway (B).
<p>Voxel-wise parametric mapping for <sup>18</sup>F-FCWAY (A) and <sup>18</sup>F-Mefway (B).</p
Radiometallic Complexes of DO3A-Benzothiazole Aniline for Nuclear Medicine Theranostics
To
develop a radioactive metal complex platform for tumor theranostics,
we introduced three radiopharmaceutical derivatives of 1,4,7,10-tetraazacyclododecane-1,4,7-trisacetic
acid-benzothiazole aniline (DO3A-BTA, L1) labeled with medical radioisotopes
for diagnosis (<sup>68</sup>Ga/<sup>64</sup>Cu) and therapy (<sup>177</sup>Lu). The tumor-targeting ability of these complexes was
demonstrated in a cellular uptake experiment, in which <sup>177</sup>Lu-L1 exhibited markedly higher uptake in HeLa cells than the <sup>177</sup>Lu-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid
complex. According to in vivo positron emission tomography imaging,
high accumulation of <sup>68</sup>Ga-L1 and <sup>64</sup>Cu-L1 was
clearly visualized in the tumor site, while <sup>177</sup>Lu-L1 showed
therapeutic efficacy in therapy experiments. Consequently, this molecular
platform represents a useful approach in nuclear medicine toward tumor-theranostic
radiopharmaceuticals when <sup>68</sup>Ga-L1 or <sup>64</sup>Cu-L1
is used for diagnosis, <sup>177</sup>Lu-L1 is used for therapy, or
two of the compounds are used in conjunction with each other